Celgene Investor

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.
Technology: Drug Design
Industry: Precision Medicine
Headquarters: Summit, New Jersey, United States
Founded Date: 1986
Employees Number: 10001+
Funding Status: M&A
Investor Type: undisclosed
Investment Stage: Undisclosed
Number Of Exits: 18

Visit Website
drugsafety@celgene.com
http://twitter.com/celgene
Register and Claim Ownership